Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019
Epidemiology Outcomes, Crisis Management,
Cytokine release syndrome (CRS) mediated by IL-6 is a critical driver of COVID-19 mortality.
The authors review and discuss key immunologic effects of direct IL-6 blockade, downstream non-selective JAK inhibition, and selective JAK2 suppression to treat COVID-19-related CRS.
We provide evidence that selective targeting of IL-6 or JAK2 is well informed by existing data.
Authors: Betts BC; Young JW. Crit Care Explor 2020.
Estimated Time: 12:04 min